TY - JOUR T1 - ▼Agomelatine for major depressive episodes JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 93 LP - 96 DO - 10.1136/dtb.2010.08.0043 VL - 48 IS - 8 A2 - , Y1 - 2010/08/01 UR - http://dtb.bmj.com/content/48/8/93.abstract N2 - Relevant BNF section: BNF 4.3.4 ▼Agomelatine (Valdoxan - Servier) is an antidepressant licensed for treating patients with major depressive episodes. The drug company's website for agomelatine states that the drug acts simultaneously as a melatonin receptor agonist and a serotonin receptor antagonist and claims that it is a “major therapeutic advance in management of depression through the restoration of circadian rhythms”.1 Here we consider whether agomelatine offers significant advantage for patients with major depressive episodes. ER -